

#4

Patent  
246/180

U.S. PRO  
SCT: 465133  
JC525 09/12/16/99

---

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: )  
Elisabetto Vegeto et al. ) Group Art Unit: To Be Assigned  
Serial No.: To Be Assigned ) Examiner: To Be Assigned  
Filed: Herewith )  
For: MUTATED STEROID HORMONE )  
RECEPTORS, METHODS FOR THEIR USE )  
AND MOLECULAR SWITCH FOR GENE )  
THERAPY )

---

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.97-98, the following information is brought to the attention of the Examiner. Copies of items listed on the attached Form PTO-1449 were cited and/or provided in parent application number 09/209,981 filed December 9, 1998.

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or

---

CERTIFICATE OF MAILING  
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

---

EL088596130US  
Express Mail Label No.

---

December 16, 1999  
Date of Deposit

---

Stephanie Sherrett  
Name of Person Mailing Paper  
Stephanie Sherrett  
Signature of Person Mailing Paper

considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Information Disclosure Statement is believed to be timely in that it is being submitted under 37 CFR 1.97(b) (3) before the mailing of a first Office Action on the merits, whereby no petition or fee is required. However, if counsel for Applicant is in error in this regard, the Commissioner is requested to consider this a petition and he is authorized to charge any required petition fee to counsel's Deposit Account No. **12-2475**.

Respectfully submitted,

LYON & LYON LLP

Dated: 12/16/99

By:

  
\_\_\_\_\_  
Charles S. Berkman  
Reg. No. 38,077

CSB:sbn  
633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
(213) 489-1600